Abstracts Archive - Page 20 of 1683 - ATC Abstracts

2022 American Transplant Congress
Longitudinal Mortality Risks and Renal Functional Outcomes in Living Kidney Donors
K. Hotta¹, T. Osawa¹, I. Yokota², T. Inao², T. Tanabe¹, N. Iwahara¹, N. Shinohara¹
¹Urology, Hokkaido University Hospital, Sapporo, Japan, ²Biostatistics, Hokkaido University Graduate School of Medicine, Sapporo, Japan
*Purpose: Previous studies have suggested that living kidney donors do not have a higher risk of death or end-stage kidney disease (ESKD) than the general…
2022 American Transplant Congress
Single Cell RNAseq Analysis of Liver Transplant Rejection Reveals Highly Restricted TCR Clonal Expansion of Tissue-Resident Memory CD8⁺ T Cells That Persist Despite Corticosteroids and ATG Therapy
A. L. Peters¹, G. Begum¹, K. Roskin², E. Woodle³, D. Hildeman⁴
¹Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Department of Bioinformatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Department of Surgery, University of Cincinnati, Cincinnati, OH, ⁴Department of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: Conventional therapy for liver transplant rejection (corticosteroids and ATG) has remained unchanged for six decades, and is not infrequently met with treatment failure. Here,…
2022 American Transplant Congress
Cold Ischemia Time is More Critical for Older Donor Kidney Survival: A Machine Learning Approach
J. Kim, J. Ahn, A. Massie, D. Segev, S. Bae
Johns Hopkins, Baltimore, MD
*Purpose: Increasing utilization of kidneys from older donors is a potential solution to mitigate the organ shortage. However, older donor age is a risk factor…
2022 American Transplant Congress
Sirolimus Regimens After Kidney Transplantation: Role of Pre-Transplant Risk Factors in Modifying the Risk of Mortality in Adult Recipients
A. Santos¹, H. Ibrahim¹, M. A. Leghrouz¹, X. Wen²
¹University of Florida, Gainesville, FL, ²University of Rhode Island, Kinston, RI
*Purpose: We aimed to investigate the role of risk factors in modifying the association of sirolimus with mortality in kidney transplant (KT) recipients (KTRs).*Methods: Using…
2022 American Transplant Congress
Impact of Target Tacrolimus Levels on BK Polyomavirus DNAemia and Allograft Rejection Among Pediatric Kidney Transplant Recipients
H. Huang¹, P. Winterberg¹, R. George¹, A. Serluco², R. Liverman², I. Yildirim³, R. Garro¹
¹Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Yale University School of Medicine, New Haven, CT
*Purpose: BK Polyomavirus (BK) DNAemia is a serious and common infectious complication after kidney transplant (KT). We evaluated the impact of targeting lower tacrolimus levels…
2022 American Transplant Congress
Decellularized Human Pancreatic Extracellular Matrix-Based Physiomimetic Microenvironment for Human Islet Culture
A. Asthana¹, D. Chaimov¹, R. Tamburrini², S. J. Walker³, G. Orlando¹
¹Wake Forest Baptist Medical Center, Winston-Salem, NC, ²University of Wisconsin Hospital and Clinics, Madison, WI, ³Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC
*Purpose: Maintenance of human islet viability and function ex vivo can be a significant bottleneck for both regenerative medicine as well as tissue engineering applications.…
2022 American Transplant Congress
Stem Cell Donor-Derived CPRA Better Reflects Sensitization Than Current CPRA
K. Lindblad¹, C. Murphey², P. Lalli³, J. Lunz⁴, L. Gragert⁵
¹UNOS, Richmnd, VA, ²Southwest Immunodiagnostics, Inc., San Antonio, TX, ³Carolinas Medical Center, Charlotte, NC, ⁴LifeLink Foundation Transplant Immunology Lab, Tampa, FL, ⁵Tulane University School of Medicine, New Orleans, LA
*Purpose: The OPTN Histocompatibility Committee proposes replacing the current calculated panel reactive antibody (CPRA), based on HLA haplotype frequencies from ~14,000 deceased kidney donors, with…
2022 American Transplant Congress
Higher Proinflammatory Cytokines Are Associated with Increased Antibody Titer After a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients
A. H. Karaba¹, X. Zhu¹, S. E. Benner¹, O. Akinde¹, Y. Eby¹, K. H. Wang¹, S. Saraf², J. M. Garonzik-Wang³, S. L. Klein¹, J. R. Bailey¹, A. L. Cox¹, J. N. Blankson¹, C. M. Durand¹, D. L. Segev¹, W. A. Werbel¹, A. A. Tobian¹
¹Johns Hopkins University, Baltimore, MD, ²National Institute of Allergy and Infectious Diseases, Bethesda, MD, ³University of Wisconsin School of Medicine and Health, Madison, WI
*Purpose: Solid organ transplant recipients (SOTRs) are at increased risk for severe COVID-19 and exhibit lower antibody responses to SARS-CoV-2 vaccines. This study aimed to…
2022 American Transplant Congress
Impact of Cold Ischemia Times on 1 Year Kidney Transplant Outcomes
T. Fletchinger, L. Burdine
Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR
*Purpose: Recent organ allocation changes have increased travel and subsequent cold ischemia times (CIT) of kidney allografts. We sought to investigate the impact of prolonged…
2022 American Transplant Congress
A Randomized Phase 2 Study Of Mau868 Vs Placebo To Treat Bk Viremia In Kidney Transplant Recipients
S. Jordan¹, A. P. Limaye², B. Fischbach³, P. Sood⁴, S. Collette⁵, L. Gasink⁶, M. W. Fordyce⁷, C. J. Lin⁷, M. Hodges⁶, D. C. Brennan⁸
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Washington, Seattle, WA, ³Dallas Nephrology Associates, Inc, Dallas, TX, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, ⁶previous employee/consultant for Amplyx Pharmaceuticals, San Diego, CA, ⁷Vera Therapeutics, Inc, Brisbane, CA, ⁸Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: To assess the safety and efficacy of MAU868, a BK virus-specific monoclonal antibody, in adult kidney transplant recipients with BK viremia.*Methods: This is a…